VericelVCEL +7.76%81 Days Payable is 82.96 as of Mar. 2026, which is 4% above its 10-year median of 79.72. GuruFocus rates VCEL with a GF Score™ of 81/100 and a GF Value™ of $54.29 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 707 Biotechnology companies, Vericel ranks worse than 57.57% on this metric.
Vericel's average Accounts Payable for the
three
months ended in Mar. 2026 was $17.4 Mil. Vericel's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $19.2 Mil.
Hence, Vericel's Days Payable for the
three
months ended in Mar. 2026 was 82.96.
The historical rank and industry rank for Vericel's Days Payable or its related term are showing as below:
VCEL'
s Days Payable Range Over the Past 10 Years
Min: 57.38 Med: 79.72 Max: 129.47
Current: 79.24
During the past 13 years, Vericel's highest Days Payable was 129.47. The lowest was 57.38. And the median was 79.72.
VCEL's Days Payable is ranked worse than 57.57% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs VCEL: 79.24
Vericel's Days Payable
declined
from Mar. 2025 (113.47) to Mar. 2026 (82.96).
It may suggest that Vericelaccelerated paying its suppliers.
Vericel Days Payable Related Terms
Vericel Days Payable Historical Data
* Premium members only.
The historical data trend for Vericel's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vericel's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vericel Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vericel's Days Payable distribution charts can be found below:
* The bar in red indicates where Vericel's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vericel's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vericel (VCEL) has a Days Payable of 82.96 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vericel and its competitors. This is near median its historical median of 79.72. Over the past decade, Vericel's Days Payable has ranged from 57.38 to 129.47. According to the industry distribution chart, Vericel ranks #407 out of 707 companies in the Biotechnology industry, placing it in the top 57.6%.
Is Vericel's Days Payable too high?
Vericel's current Days Payable of 82.96 is near median its 10-year median of 79.72. Over the past 10 years, this metric has ranged from a low of 57.38 to a high of 129.47. The Biotechnology industry median Days Payable is 113.76. Vericel's value of 82.96 is 27.1% below this industry median. Based on the distribution chart, Vericel ranks #407 out of 707 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vericel has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's Days Payable compare to PVLA and TSHA?
According to the Biotechnology industry distribution chart, Vericel ranks #407 out of 707 companies for Days Payable. This places Vericel in the lower half of its industry. The industry median Days Payable is 113.76. Vericel's value of 82.96 is 27.1% below this benchmark. Historically, Vericel's own Days Payable has ranged from 57.38 to 129.47 over the past decade. While the company's 10-year median is 79.72 vs. the industry median of 113.76, Vericel has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vericel's current Days Payable of 82.96 is 27.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vericel and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vericel's current Days Payable is 82.96, which is near median its own 10-year median of 79.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (VCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $54.29, compared to a current price of $46.23 — trading 14.8% below its estimated fair value. The current Days Payable is 82.96, which is near median its 10-year median of 79.72 and 27.1% below the Biotechnology industry median of 113.76. Vericel's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vericel (VCEL), the current Days Payable is 82.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vericel (VCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Vericel stock appears to be undervalued.
The current stock price of $46.23 is trading 14.8% below its estimated GF Value™ of $54.29.
GuruFocus considers Vericel to be Modestly Undervalued.
Key valuation signals for VCEL:
Days Payable: 82.96 (near median its 10-year median of 79.72)
GF Value™: $54.29 vs. price of $46.23 (14.8% below fair value)
Industry Position: 27.1% below the Biotechnology median (#407 of 707)
No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
81GF Score
Get the complete analysis for VCEL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCEL has been successfully added to your 
